3-Feb-2026
Agios Expands Rare-Disease Pipeline With New Phase 1b PKU Study of AG-181
TipRanks (Fri, 30-Jan 11:32 AM ET)
Globe Newswire (Mon, 26-Jan 7:00 AM ET)
Globe Newswire (Mon, 12-Jan 7:00 AM ET)
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Globe Newswire (Mon, 5-Jan 7:00 AM ET)
FDA Approves Agios’ AQVESME as First and Only Therapy for Anemia in Both Alpha- and Beta-Thalassemia
Market Chameleon (Wed, 24-Dec 2:32 AM ET)
Globe Newswire (Tue, 23-Dec 7:45 PM ET)
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
Globe Newswire (Mon, 8-Dec 7:00 AM ET)
Market Chameleon (Thu, 20-Nov 5:35 AM ET)
Market Chameleon (Wed, 19-Nov 2:33 AM ET)
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
Globe Newswire (Wed, 19-Nov 7:00 AM ET)
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Agios Pharmaceuticals trades on the NASDAQ stock market under the symbol AGIO.
As of February 3, 2026, AGIO stock price declined to $27.93 with 612,351 million shares trading.
AGIO has a beta of 1.97, meaning it tends to be more sensitive to market movements. AGIO has a correlation of 0.23 to the broad based SPY ETF.
AGIO has a market cap of $1.63 billion. This is considered a Small Cap stock.
Last quarter Agios Pharmaceuticals reported $13 million in Revenue and -$1.78 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.14.
In the last 3 years, AGIO traded as high as $62.58 and as low as $19.80.
The top ETF exchange traded funds that AGIO belongs to (by Net Assets): XBI, VTI, IWM, VB, VBK.
AGIO has underperformed the market in the last year with a return of -18.8%, while the SPY ETF gained +15.8%. In the last 3 month period, AGIO fell short of the market, returning -35.4%, while SPY returned +1.4%. However, in the most recent 2 weeks AGIO has outperformed the stock market by returning +2.7%, while SPY returned -0.3%.
AGIO support price is $27.35 and resistance is $28.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGIO shares will trade within this expected range on the day.